Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.

Holistic and Multidisciplinary Approaches to Multiple Myeloma Management

September 25th 2023

Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.

Impact of Clinical Trials on the Management of Multiple Myeloma

September 25th 2023

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

Dr Usmani on Unmet Needs in the Treatment of High-Risk Multiple Myeloma

September 22nd 2023

Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Dr Chari on the Evolving Role of Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma

September 20th 2023

Ajai Chari, MD, discusses the evolving role of bispecific antibodies and CAR T-cell therapies, such as ciltacabtagene autoleucel, in the treatment of patients with multiple myeloma.

Dr Chari on Currently Available Bispecific Antibodies in Multiple Myeloma

September 18th 2023

Ajai Chari, MD, director, discusses the current landscape of bispecific antibodies in relapsed/refractory multiple myeloma.

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab mafodotin-blmf for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior treatments.

Importance of Clinical Trial Enrollment in Multiple Myeloma

September 18th 2023

Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.

Multiple Myeloma: Regulatory Aspects of Treatment Development and Approval

September 18th 2023

A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.

Dr Usmani on Identifying High-Risk Patients With Multiple Myeloma

September 15th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses methods for identifying patients with high-risk multiple myeloma and notable disease characteristics in this population.

Dr Chari on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

September 14th 2023

Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.

Extended Melphalan Flufenamide Indication Approaches EU Approval for R/R Multiple Myeloma

September 14th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding a Type II variation application to extend the therapeutic indication of melphalan flufenamide for use in adult patients with multiple myeloma who have received at least 2 prior lines of treatment and whose disease is refractory to lenalidomide and the last line of therapy.

Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple Myeloma

September 12th 2023

Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.

Dr Costa on the Clinical Implications of the MASTER Trial in Multiple Myeloma

September 11th 2023

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma

September 11th 2023

The FDA has approved motixafortide (Aphexda) in combination with filgrastim (Neupogen) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplant in patients with multiple myeloma.

Educating Patients on Treatment Options for Multiple Myeloma

September 11th 2023

Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.

Treatment for Newly Diagnosed Multiple Myeloma: Addressing Disparities in Care

September 11th 2023

Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Chari Highlights Nuances of Choosing Between CAR T-cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 8th 2023

Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.